STOCK TITAN

Accuray Incorp - ARAY STOCK NEWS

Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.

Company Overview

Accuray Incorp (NASDAQ: ARAY) is a pioneering radiation oncology company dedicated to developing, manufacturing, and supporting innovative treatment solutions. With its robust portfolio of advanced radiotherapy systems, Accuray stands out in the field of robotic radiosurgery and precision radiation treatment. Technologies such as CyberKnife and Radixact integrate real-time tracking, advanced imaging, and dynamic treatment planning to deliver sub-millimetre accuracy when treating tumors. This unique blend of robotics and radiation therapy is essential for accurate, effective, and efficient cancer treatment.

Core Technologies and Capabilities

Accuray’s solutions are designed to meet the complex needs of modern oncology. The company’s systems automatically track and adjust to patient and tumor motion, ensuring delivery of high doses of radiation with exceptional precision. Key technologies include:

  • Real-Time Motion Tracking: Automated tracking systems that detect and correct patient movements during treatment.
  • Advanced Imaging Integration: Solutions like ClearRT provide diagnostic-quality imaging to guide therapy, ensuring optimal patient positioning and treatment accuracy.
  • Adaptive Treatment Planning: Innovative planning systems such as the Accuray Precision TPS allow clinicians to adapt treatment plans in real-time, accounting for changes in tumor characteristics and patient anatomy.
  • Robotic Radiosurgery: The CyberKnife System is a testament to the integration of robotics with medical imaging, delivering ultra-hypofractionated treatments in just a few outpatient sessions.

Market Position and Business Model

Accuray operates in a competitive global market characterized by rapid technological advances and high clinical demands. The company’s business model is built around the development and commercialization of cutting-edge devices that support a complete continuum of care—from pre-treatment planning to post-treatment care. By partnering with hospitals, cancer centers, and clinicians, Accuray not only provides state-of-the-art equipment but also offers training and support services, enhancing operational efficiencies in radiation oncology departments.

Innovation and Industry Influence

Innovation is at the heart of Accuray’s operations. The constantly evolving product portfolio, which includes enhancements in imaging, treatment planning, and adaptive delivery technologies, has positioned the company as a critical player in improving patient access to high-precision radiotherapy. These innovations have garnered recognition across global markets, particularly in regions with growing demand for advanced cancer care solutions.

Clinical Impact and Patient Care

The primary goal of Accuray’s technologies is to help patients live longer and better lives by offering treatments that are both effective and minimally disruptive. The advanced radiation therapy systems are designed to reduce treatment times, lower the risk of side effects, and deliver high-quality, personalized care. Clinicians benefit from enhanced workflow efficiencies and the ability to treat a diverse range of cancers—from common malignancies to complex cases that require sophisticated robotic surgery.

Operational Excellence and Global Reach

Headquartered in the United States with a worldwide network of facilities, Accuray has established a robust presence in both developed and emerging markets. The company’s strategic partnerships and joint ventures allow it to tailor its products to local market needs, ensuring that precise radiation therapies are available where they are needed most. This global footprint, combined with continuous investment in research and development, makes Accuray a respected name in radiation oncology.

Conclusion

Through its commitment to technical excellence and innovation, Accuray Incorp delivers comprehensive radiotherapy treatment solutions that set the standard of care in radiation oncology. The company’s integrated approach—leveraging advanced technologies to meet complex clinical challenges—has redefined the possibilities in tumor treatment. Investors and industry analysts recognize Accuray not only for its state-of-the-art products but also for its sustainable business model and its pivotal role in enhancing global patient care in radiation therapy.

Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) presented new data at the 2024 Radiosurgery Society Meeting supporting the use of the CyberKnife System in treating high-risk and recurrent prostate cancer. The system's precision with stereotactic body radiation therapy (SBRT) offers effective treatment in 4-5 sessions compared to traditional therapy. The data highlighted favorable outcomes, low toxicities, and the system's ability to track and correct for prostate movement during treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the 36th Annual Roth Conference with a fireside chat on March 18, 2024. The event will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
-
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12-13, 2024. The management team will engage in a fireside chat on March 12, 2024, at 7:00am PST / 10:00am EST. Investors can access the live webcast on the Accuray website with a replay available post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) partners with Montérégie Integrated Cancer Center to introduce Radixact System for cancer treatment in Quebec. The system includes ClearRT™ and Synchrony® technologies to enhance treatment outcomes and minimize side effects. The center aims to set a new standard in precision and accuracy for radiation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) is set to participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024. The event is exclusive to BTIG clients, offering the opportunity for one-on-one meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
conferences
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) reported a 19% increase in gross orders, 8% service revenue expansion, and confirmed FY24 guidance. Net revenue for the second quarter of fiscal 2024 was $107.2 million, a 3% sequential increase and a 7% decrease from the same period in the prior fiscal year. GAAP net loss was $9.6 million, compared to $1.9 million in the prior fiscal year. Adjusted EBITDA was $2.0 million, compared to $8.5 million in the same period in the prior fiscal year. The company also reported a 6% increase in gross orders for the first six months of fiscal 2024 and reaffirmed guidance for fiscal year 2024, expecting total revenue in the range of $460 million to $470 million, representing a year-over-year growth range of 3 to 5 percent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife S7 System, the hospital's second CyberKnife radiation delivery device purchase. The precision and accuracy enabled by the system's robotic design will also make it an ideal choice for the treatment of neurologic disorders. The new system will enable the medical team to deliver gold standard stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments faster than with previous models, expanding access to an effective and convenient option to more patients. The CyberKnife S7 System is a non-invasive radiation therapy device that was built from the ground-up to provide clinicians with the speed they need for operational efficiency without sacrificing the precision and accuracy required for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2024, ended December 31, 2023, during a conference call on January 31, 2024. The conference call will be hosted by company management and a live webcast will be available. Investors can access the webcast replay from the Investor Relations section of the company's website. The dial-in numbers for the conference call and the replay numbers are provided for both USA and international participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) has initiated sales of the VitalHold™ package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan. The VitalHold feature incorporates SGRT capability on the Radixact System using the Catalyst+ HD system manufactured by C-RAD, enabling medical teams to offer a wider range of radiotherapy treatment options using one device. This new feature will make it possible to deliver deep inspiration breath hold (DIBH) treatments, primarily for breast cancers, and perform markerless patient setup, reducing the burden on medical staff and patients. The introduction of the VitalHold package is a significant technological innovation for the Radixact System, enhancing its functionality and versatility in the Japanese market, where over 100 units are routinely used to treat cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags

FAQ

What is the current stock price of Accuray Incorp (ARAY)?

The current stock price of Accuray Incorp (ARAY) is $1.48 as of April 18, 2025.

What is the market cap of Accuray Incorp (ARAY)?

The market cap of Accuray Incorp (ARAY) is approximately 150.1M.

What does Accuray Incorp specialize in?

Accuray focuses on developing, manufacturing, and supporting advanced radiation therapy systems for oncology, including robotic radiosurgery solutions.

What are some key technologies developed by Accuray?

Key technologies include the CyberKnife System, Radixact platforms, ClearRT imaging solutions, Synchrony real-time tracking, and adaptive treatment planning systems.

How do Accuray's systems improve cancer treatment?

Their systems deliver high doses of radiation with sub-millimetre accuracy, continuously tracking patient and tumor movements to ensure precise targeting and reduce treatment side effects.

Who are the primary customers of Accuray?

Primary customers include hospitals, cancer centers, and oncology clinics worldwide that require advanced radiotherapy solutions for effective patient care.

How does Accuray maintain its position in a competitive market?

Accuray invests heavily in R&D, forging strategic partnerships and joint ventures in emerging markets, and continuously innovates its product portfolio to meet evolving clinical needs.

What benefits does real-time tracking technology offer?

Real-time tracking technology automatically adjusts for patient and tumor movement, enhancing treatment precision and allowing clinicians to deliver effective radiation therapy with reduced risk to healthy tissues.

How is Accuray contributing to global cancer care?

By providing advanced, market-changing solutions that simplify complex treatments and expand patient access to precision radiotherapy, Accuray significantly enhances clinical outcomes worldwide.
Accuray Incorp

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

150.13M
100.18M
2.53%
60.86%
4.18%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MADISON